A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare progression-free survival (PFS) between Arm A
(ociperlimab in combination with tislelizumab) and Arm B (pembrolizumab in combination with
placebo) as assessed by investigators according to Response Evaluation Criteria in Solid
Tumors Version 1.1 (RECIST v1.1) and to compare overall survival (OS) between Arm A and Arm
B.